Jin Medical International Ltd. (ZJYL) - Form 20-F Summary
Business Context and Reporting Period
Company: Jin Medical International Ltd. (Jin Med)
Reporting Period: Fiscal year ended September 30, 2025
Structure: Cayman Islands holding company operating through a Variable Interest Entity (VIE) structure in the People's Republic of China (PRC). The VIE, Changzhou Zhongjin Medical Co., Ltd., and its subsidiaries conduct all manufacturing and sales operations.
Operations: Design, manufacture, and sale of wheelchairs and living aids products (e.g., oxygen concentrators, bathing machines). Primary markets are Japan and China.
Listing: Nasdaq Capital Market (Symbol: ZJYL).
Key Financial Metrics (Fiscal Year Ended Sept 30, 2025)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $20,687,274 | $23,502,010 | $19,821,457 |
| Net Income (Attributable to Jin Med) | $1,191,297 | $3,675,927 | $2,878,230 |
| Gross Profit | $6,044,533 | $9,502,769 | $6,784,834 |
| Gross Margin | 29.2% | 40.4% | 34.2% |
| Operating Income | $608,182 | $3,638,748 | $2,867,262 |
| Cash and Cash Equivalents | $7,461,630 | $8,136,179 | $6,929,508 |
| Short-Term Investments | $22,168,607 | $18,621,251 | N/A |
| Short-Term Bank Loans | $18,837,468 | $11,322,440 | N/A |
| Working Capital | $20,347,322 | $25,664,082 | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 12.0% to $20.7 million in 2025 compared to 2024. This was primarily driven by a $4.2 million decrease in revenue from "other products" (nano products, oxygen chambers, beauty instruments) due to slower market adoption than projected. This decline was partially offset by a $1.4 million increase in wheelchair revenue, driven by increased orders from the largest customer, Nissin.
- Profitability Drop: Net income attributable to Jin Med fell 67.6% to $1.19 million. Operating income dropped 83.3% to $0.61 million. The decline was exacerbated by a significant compression in gross margin (down 11.2 percentage points to 29.2%) due to the shift in product mix toward lower-margin items and higher variable costs for standard wheelchairs.
- Debt Increase: Short-term bank loans increased by approximately $7.5 million to $18.8 million to fund the construction of a new manufacturing facility in Chuzhou City, Anhui.
- Customer Concentration: Nissin and its subsidiaries accounted for approximately 71.0% of total revenue in 2025, up from 57.3% in 2024.
Guidance, Outlook, and Risks
Outlook & Strategy:
- Construction: A new manufacturing facility is under construction to expand capacity for premium mobility products. Completion is expected in April 2026, with future expenditures estimated at $3.4 million.
- Product Mix: Management is engaging a new sales team to improve the performance of new product lines (nano products, oxygen chambers) which underperformed in 2025.
- Capital Needs: The company believes current cash, operating cash flows, and borrowings are sufficient for the foreseeable future but may require additional financing if growth accelerates or adverse conditions arise.
- VIE Structure Risk: The company relies on contractual arrangements to control its PRC operating entities. If PRC authorities invalidate these arrangements, the company could lose control of its assets and operations, potentially rendering shares worthless.
- Customer Concentration: Heavy reliance on Nissin (71% of revenue) poses a significant risk; loss of this customer would materially impact operations.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including a lack of accounting staff with U.S. GAAP knowledge and lack of formal controls over financial closing. Remediation is ongoing.
- Nasdaq Compliance: The company received a notice of non-compliance with the minimum bid price requirement ($1.00) in May 2025. It is currently in a compliance period and may implement a reverse share split to regain compliance.
- Regulatory Environment: Risks related to PRC regulations on overseas listings, data security, and the "Holding Foreign Companies Accountable Act" (HFCA) regarding PCAOB inspections.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of the 12% revenue decline and the specific sales trajectory of the "other products" category which drove the drop.
- Margin Compression: Investigate the reasons for the gross margin drop from 40.4% to 29.2% and whether this is a structural shift or temporary.
- Internal Control Remediation: Confirm the progress of hiring qualified accounting personnel and implementing formal financial closing controls to address material weaknesses.
- Nasdaq Status: Monitor the company's ability to regain compliance with the minimum bid price requirement to avoid delisting.
- Customer Dependency: Assess the stability of the relationship with Nissin, which accounts for the vast majority of revenue, and the lack of long-term supply agreements.
- Debt Servicing: Review the terms of the increased short-term debt ($18.8M) and the company's ability to service these loans given the decline in operating income.